慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)简称慢阻肺,是呼吸系统的常见疾病,慢阻肺患者最常见诱因为呼吸道感染,此类病人机体免疫力低下、长期吸入糖皮质激素控制病情,在此期间最易引起结核分枝杆菌的感染,因此慢阻肺合并肺结核的患者更难以治疗,两病共存以及相互影响使疾病的诊断和治疗存在难度,增加患者的死亡风险。本文从慢阻肺合并肺结核的危险因素、临床特点、影像学特点、肺功能以及治疗等方面进行综述。 Chronic obstructive pulmonary disease (COPD), also known as chronic obstructive pulmonary dis-ease (COPD), is a common respiratory disease. Patients with COPD are the most common cause of respiratory infections, and their immune system is low. Long term inhalation of corticosteroids to control the condition is the most likely cause of infection with Mycobacterium tuberculosis during this period. Therefore, patients with COPD combined with pulmonary tuberculosis are more difficult to treat. The coexistence and mutual influence of two diseases make the diagnosis and treatment of the disease difficult, increasing the risk of death for patients. This article reviews the risk factors, clinical characteristics, imaging features, pulmonary function, and treatment of chronic obstructive pulmonary disease (COPD) complicated with pulmonary tuberculosis.
慢性阻塞性肺疾病,肺结核,两病共存,临床研究, Chronic Obstructive Pulmonary Disease
Pulmonary Tuberculosis
Coexistence of Two Diseases
Clinical Study
摘要
Chronic obstructive pulmonary disease (COPD), also known as chronic obstructive pulmonary disease (COPD), is a common respiratory disease. Patients with COPD are the most common cause of respiratory infections, and their immune system is low. Long term inhalation of corticosteroids to control the condition is the most likely cause of infection with Mycobacterium tuberculosis during this period. Therefore, patients with COPD combined with pulmonary tuberculosis are more difficult to treat. The coexistence and mutual influence of two diseases make the diagnosis and treatment of the disease difficult, increasing the risk of death for patients. This article reviews the risk factors, clinical characteristics, imaging features, pulmonary function, and treatment of chronic obstructive pulmonary disease (COPD) complicated with pulmonary tuberculosis.
Keywords:Chronic Obstructive Pulmonary Disease, Pulmonary Tuberculosis, Coexistence of Two Diseases, Clinical Study
刘敬璞,崔金霞. 慢性阻塞性肺疾病合并肺结核的临床研究Clinical Study on Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Tuberculosis[J]. 临床医学进展, 2023, 13(06): 9844-9850. https://doi.org/10.12677/ACM.2023.1361377
参考文献References
Raherison, C. and Girodet, P. (2009) Epidemiology of COPD. European Respiratory Review, 18, 213-221. https://doi.org/10.1183/09059180.00003609
Singh, D., Agusti, A., Anzueto, A., et al. (2019) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The GOLD Science Committee Report 2019. European Respiratory Journal, 53, Article ID: 1900164. https://doi.org/10.1183/13993003.00164-2019
Chai, Q., Lu, Z., Liu, Z., et al. (2020) Lung Gene Expression Signatures Suggest Pathogenic Links and Molecular Markers for Pulmonary Tuberculosis, Adenocarcinoma and Sar-coidosis. Communications Biology, 3, Article No. 604. https://doi.org/10.1038/s42003-020-01318-0
Harding, E. (2020) WHO Global Progress Report on Tuberculo-sis Elimination. The Lancet Respiratory Medicine, 8, Article No. 19. https://doi.org/10.1016/S2213-2600(19)30418-7
Lee, C.-H., Lee, M.-C., Lin, H.-H., et al. (2012) Pulmonary Tuberculosis and Delay in Anti-Tuberculous Treatment Are Important Risk Factors for Chronic Obstructive Pulmonary Disease. PLOS ONE, 7, e37978. https://doi.org/10.1371/journal.pone.0037978
Polverino, F. and Kheradmand, F. (2021) COVID-19, COPD, and AECOPD: Immunological, Epidemiological, and Clinical Aspects. Frontiers in Medicine, 7, Article ID: 627278. https://doi.org/10.3389/fmed.2020.627278
Chakrabarti, B., Calverley, P.M. and Davies, P.D. (2007) Tuber-culosis and Its Incidence, Special Nature, and Relationship with Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease, 2, 263-272.
Shimeles, E., Enquselassie, F., Aseffa, A., et al. (2019) Risk Factors for Tuberculosis: A Case-Control Study in Addis Ababa, Ethiopia. PLOS ONE, 14, e0214235. https://doi.org/10.1371/journal.pone.0214235
Papi, A., Bellettato, C.M., Braccioni, F., et al. (2006) Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations. American Journal of Res-piratory and Critical Care Medicine, 173, 1114-1121. https://doi.org/10.1164/rccm.200506-859OC
Mallia, P., Contoli, M., Caramori, G., et al. (2007) Exacerbations of Asthma and Chronic Obstructive Pulmonary Disease (COPD): Focus on Virus Induced Exacerbations. Current Pharmaceutical Design, 13, 73-97. https://doi.org/10.2174/138161207779313777
Han, M.K., Quibrera, P.M., Carretta, E.E., et al. (2017) Fre-quency of Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: An Analysis of the SPIROMICS Cohort. The Lancet Respiratory Medicine, 5, 619-626. https://doi.org/10.1016/S2213-2600(17)30207-2
Attaway, A.A., Zein, J. and Hatipoğlu, U.S. (2020) SARS-CoV-2 Infection in the COPD Population Is Associated with Increased Healthcare Utilization: An Analysis of Cleveland Clinic’s COVID-19 Registry. EClinicalMedicine, 26, Article ID: 100515. https://doi.org/10.1016/j.eclinm.2020.100515
Agusti, A., Fabbri, L.M., Singh, D., et al. (2018) Inhaled Corti-costeroids in COPD: Friend or Foe? European Respiratory Journal, 52, Article ID: 1801219. https://doi.org/10.1183/13993003.01219-2018
Brassard, P., Suissa, S., Kezouh, A., et al. (2011) Inhaled Cor-ticosteroids and Risk of Tuberculosis in Patients with Respiratory Diseases. American Journal of Respiratory and Criti-cal Care Medicine, 183, 675-678. https://doi.org/10.1164/rccm.201007-1099OC
Fan, H., Wu, F., Liu, J., et al. (2021) Pulmonary Tuberculosis as a Risk Factor for Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. Annals of Translational Medicine, 9, Article No. 390. https://doi.org/10.21037/atm-20-4576
Hooper, R., Burney, P., Vollmer, W.M., et al. (2012) Risk Factors for COPD Spirometrically Defined from the Lower Limit of Normal in the BOLD Project. European Respiratory Journal, 39, 1343-1353. https://doi.org/10.1183/09031936.00002711
Wada, H., Ikeda, A., Maruyama, K., et al. (2021) Low BMI and Weight Loss Aggravate COPD Mortality in Men, Findings from a Large Prospective Cohort: The JACC Study. Scientific Reports, 11, Article No. 1531. https://doi.org/10.1038/s41598-020-79860-4
Gläser, S., Krüger, S., Merkel, M., et al. (2015) Chronic Ob-structive Pulmonary Disease and Diabetes Mellitus: A Systematic Review of the Literature. Respiration, 89, 253-264. https://doi.org/10.1159/000369863
Ma, L., Chen, X. and Gao, M. (2022) Analysis on the Risk Factors of Malnutrition in Type 2 Diabetes Mellitus Patients with Pulmonary Tuberculosis. Infection and Drug Resistance, 15, 7555-7564. https://doi.org/10.2147/IDR.S381392
Wang, X., Luo, L., Zhang, D., et al. (2022) Factors Associated with Nutritional Risk in Patients with Pulmonary Tuberculosis and Structural Lung Disease: A Hospital-Based Cross-Sectional Study. Journal of Multidisciplinary Healthcare, 15, 1799-1807. https://doi.org/10.2147/JMDH.S375441
Chu, A.L., Lecca, L.W., Calderón, R.I., et al. (2021) Smoking Cessa-tion in Tuberculosis Patients and the Risk of Tuberculosis Infection in Child Household Contacts. Clinical Infectious Diseases, 73, 1500-1506. https://doi.org/10.1093/cid/ciab504
Park, H.Y., Kang, D., Shin, S.H., et al. (2022) Pulmonary Tuberculosis and the Incidence of Lung Cancer among Patients with Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 19, 640-648. https://doi.org/10.1513/AnnalsATS.202010-1240OC
Nnoaham, K.E. and Clarke, A. (2008) Low Serum Vit-amin D Levels and Tuberculosis: A Systematic Review and Meta-Analysis. International Journal of Epidemiology, 37, 113-119. https://doi.org/10.1093/ije/dym247
Svanes, C., Sunyer, J., Plana, E., et al. (2010) Early Life Origins of Chronic Obstructive Pulmonary Disease. Thorax, 65, 14-20. https://doi.org/10.1136/thx.2008.112136
Sarkar, M., Madabhavi, I. and Kumar, K. (2017) Tuberculosis Asso-ciated Chronic Obstructive Pulmonary Disease. The Clinical Respiratory Journal, 11, 285-295. https://doi.org/10.1111/crj.12621
Kanervisto, M., Vasankari, T., Laitinen, T., et al. (2011) Low Socioeconomic Status Is Associated with Chronic Obstructive Airway Diseases. Respiratory Medicine, 105, 1140-1146. https://doi.org/10.1016/j.rmed.2011.03.008
Sakornsakolpat, P., Prokopenko, D., Lamontagne, M., et al. (2019) Genetic Landscape of Chronic Obstructive Pulmonary Disease Identifies Heterogeneous Cell-Type and Phenotype Asso-ciations. Nature Genetics, 51, 494-505. https://doi.org/10.1038/s41588-018-0342-2
Ma, L. and Gao, M. (2022) Analysis of Clinical Characteristics and Risk Factors for Drug Resistance in Newly-Treated Patients with Pulmonary Tuberculosis Complicated with Chronic Obstructive Pulmonary Disease. Infection and Drug Resistance, 15, 4861-4869. https://doi.org/10.2147/IDR.S358121
Menezes, A.M.B., Hallal, P.C., Perez-Padilla, R., et al. (2007) Tuber-culosis and Airflow Obstruction: Evidence from the PLATINO Study in Latin America. European Respiratory Journal, 30, 1180-1185. https://doi.org/10.1183/09031936.00083507
Matheson, M.C., Bowatte, G., Perret, J.L., et al. (2018) Predic-tion Models for the Development of COPD: A Systematic Review. International Journal of Chronic Obstructive Pul-monary Disease, 13, 1927-1935. https://doi.org/10.2147/COPD.S155675
Lee, J. and Chang, J. (2003) Lung Function in Patients with Chronic Airflow Obstruction Due to Tuberculous Destroyed Lung. Respiratory Medicine, 97, 1237-1242. https://doi.org/10.1016/S0954-6111(03)00255-5
Wang, Y., Li, Z. and Li, F. (2023) Impact of Previous Pul-monary Tuberculosis on Chronic Obstructive Pulmonary Disease: Baseline Results from a Prospective Cohort Study. Combinatorial Chemistry & High Throughput Screening, 26, 93-102. https://doi.org/10.2174/1386207325666220406111435
Kadowaki, T., Yano, S., Wakabayashi, K., et al. (2011) Pulmonary Tuberculosis with Atypical Radiological Findings in a Patient with Chronic Obstructive Pulmonary Disease. Kekkaku [Tuberculosis], 86, 763-766.
Jung, J.-W., Choi, J.-C., Shin, J.-W., et al. (2015) Pulmonary Impairment in Tuberculosis Survivors: The Korean National Health and Nutrition Examination Survey 2008-2012. PLOS ONE, 10, e0141230. https://doi.org/10.1371/journal.pone.0141230
Jin, J., Li, S., Yu, W., et al. (2018) Emphysema and Bronchiec-tasis in COPD Patients with Previous Pulmonary Tuberculosis: Computed Tomography Features and Clinical Implica-tions. International Journal of Chronic Obstructive Pulmonary Disease, 13, 375-384. https://doi.org/10.2147/COPD.S152447
Pefura-Yone, E.W., Kengne, A.P., Tagne-Kamdem, P.E., et al. (2014) Clinical Significance of Low Forced Expiratory Flow between 25% and 75% of Vital Capacity Following Treated Pul-monary Tuberculosis: A Cross-Sectional Study. BMJ Open, 4, e005361. https://doi.org/10.1136/bmjopen-2014-005361
Nishi, M.P., Mancuzo, E.V., Sulmonett, N., et al. (2021) Pul-monary Functional Assessment: Longitudinal Study after Treatment of Pulmonary Tuberculosis. Revista do Instituto de Medicina Tropical de São Paulo, 63, e65. https://doi.org/10.1590/s1678-9946202163065
Tiberi, S., Zumla, A. and Migliori, G.B. (2019) Multidrug and Extensively Drug-Resistant Tuberculosis: Epidemiology, Clinical Features, Management and Treatment. Infectious Dis-ease Clinics, 33, 1063-1085. https://doi.org/10.1016/j.idc.2019.09.002
Shadrach, B.J., Kumar, S., Deokar, K., et al. (2021) A Study of Multidrug Resistant Tuberculosis among Symptomatic Household Contacts of MDR-TB Patients. Indian Journal of Tu-berculosis, 68, 25-31. https://doi.org/10.1016/j.ijtb.2020.09.030
Chung, K.-P., Chen, J.-Y., Lee, C.-H., et al. (2011) Trends and Pre-dictors of Changes in Pulmonary Function after Treatment for Pulmonary Tuberculosis. Clinics, 66, 549-556. https://doi.org/10.1590/S1807-59322011000400005